Overexpression of TRPV6 Inhibits Coronary Atherosclerosis-Related Inflammatory Response and Cell Apoptosis via the PKA/UCP2 Pathway.

Publisher: Hindawi Country of Publication: England NLM ID: 101319630 Publication Model: eCollection Cited Medium: Internet ISSN: 1755-5922 (Electronic) Linking ISSN: 17555914 NLM ISO Abbreviation: Cardiovasc Ther Subsets: MEDLINE

Publication: 2019- : [London, United Kingdom] : Hindawi
Original Publication: Oxford : Wiley-Blackwell, c2008-c2018.

Apoptosis* ; TRPV Cation Channels*/genetics ; TRPV Cation Channels*/metabolism ; Cyclic AMP-Dependent Protein Kinases*/metabolism ; Signal Transduction* ; Coronary Artery Disease*/pathology ; Coronary Artery Disease*/genetics ; Coronary Artery Disease*/metabolism ; Disease Models, Animal* ; Mice, Inbred C57BL* ; Uncoupling Protein 2*/genetics ; Uncoupling Protein 2*/metabolism; Animals ; Humans ; Male ; Calcium Channels/metabolism ; Calcium Channels/genetics ; Inflammation Mediators/metabolism ; Mice, Knockout, ApoE ; Plaque, Atherosclerotic ; Human Umbilical Vein Endothelial Cells/metabolism ; Human Umbilical Vein Endothelial Cells/pathology ; Human Umbilical Vein Endothelial Cells/enzymology ; Cytokines/metabolism ; Cytokines/genetics ; Lipoproteins, LDL/metabolism

Competing Interests: The authors declare no conflicts of interest.
Objective: This research is aimed at unravelling the intricate relationship between transient receptor potential vanilloid 6 (TRPV6), protein kinase A (PKA), uncoupling protein 2 (UCP2), and atherosclerosis. By shedding light on the role of the TRPV6/PKA/UCP2 pathway in inhibiting inflammatory response and cell apoptosis in coronary atherosclerotic plaques, this study provides valuable insights into potential therapeutic targets for treating coronary artery disease (CAD). Methods: We established animal and cell models of atherosclerosis. The expression of TRPV6 was measured using immunohistochemistry and immunofluorescence. Cytokine levels were detected by enzyme-linked immunosorbent assay (ELISA). Cell viability and apoptosis ratio were measured using cell counting kit-8 (CCK-8) and flow cytometry. The binding relationship between TRPV6 and PKA was validated using chromatin immunoprecipitation (CHIP) and coimmunoprecipitation (CoIP). Finally, the expression of the TRPV6/PKA/UCP2 signaling pathway and apoptosis-related factors was detected using western blot (WB) and quantitative real-time polymerase chain reaction (qRT-PCR). Results: TRPV6 was significantly decreased in atherosclerosis mouse and cell model. CHIP and CoIP assays indicated that TRPV6 binds to PKA and positively regulated its expression in oxidized low-density lipoprotein (ox-LDL)-treated human umbilical vein endothelial cells (HUVECs). Overexpression of TRPV6 significantly increased cell viability and inhibited apoptosis, whereas silencing TRPV6 had the opposite effect. Additionally, the overexpression of TRPV6 remarkably declined the expression of tumor necrosis factor-alpha (TNF- α ), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 β ). However, after silencing PKA, this effect was partially reversed, the cell viability and inflammatory response remarkably enhanced, and apoptosis significantly declined in oe-TRPV6 + si-PKA group. Conclusions: In summary, our study demonstrated that TRPV6 inhibited apoptosis and inflammatory response in the atherosclerosis cell model through the regulation of the PKA/UCP2 pathway.
(Copyright © 2024 Lei Zheng et al.)

Hypertension. 2013 Jan;61(1):246-52. (PMID: 23150506)
Ann Clin Lab Sci. 2020 Nov;50(6):775-780. (PMID: 33334793)
Curr Opin Lipidol. 2022 Oct 1;33(5):283-288. (PMID: 35942822)
Nutrients. 2020 Jul 07;12(7):. (PMID: 32645995)
Signal Transduct Target Ther. 2022 Apr 22;7(1):131. (PMID: 35459215)
Cells. 2022 Apr 22;11(9):. (PMID: 35563730)
Biochim Biophys Acta. 2007 Apr;1773(4):565-76. (PMID: 17292493)
Mediators Inflamm. 2020 Mar 23;2020:6420425. (PMID: 32273830)
Cancers (Basel). 2023 Mar 17;15(6):. (PMID: 36980711)
Cell Biosci. 2018 Jan 19;8:4. (PMID: 29387339)
J Mol Cell Cardiol. 2018 Jul;120:1-11. (PMID: 29758225)
Basic Res Cardiol. 2015 Nov;110(6):54. (PMID: 26415881)
Acta Pharmacol Sin. 2022 Apr;43(4):811-828. (PMID: 34183754)
J Leukoc Biol. 2010 May;87(5):895-904. (PMID: 20103769)
Cancer Lett. 2021 Oct 28;519:150-160. (PMID: 34265397)
BMC Med. 2013 May 01;11:117. (PMID: 23635324)
Biomedicines. 2021 Sep 14;9(9):. (PMID: 34572406)
Gastroenterology. 2020 May;158(6):1626-1641.e8. (PMID: 31930989)
Circulation. 2005 Jun 28;111(25):3481-8. (PMID: 15983262)
Hypertension. 2016 Feb;67(2):451-60. (PMID: 26667415)
Transl Res. 2013 Jun;161(6):469-76. (PMID: 23453732)
Front Pharmacol. 2021 Aug 24;12:723922. (PMID: 34504429)
Commun Biol. 2021 Aug 19;4(1):990. (PMID: 34413465)
J Epidemiol Glob Health. 2021 Jun;11(2):169-177. (PMID: 33605111)
J Cell Sci. 2021 Oct 15;134(20):. (PMID: 34545403)
Int J Mol Sci. 2020 May 31;21(11):. (PMID: 32486345)
Channels (Austin). 2020 Dec;14(1):141-150. (PMID: 32274960)
Front Immunol. 2023 Jan 31;14:1093584. (PMID: 36817471)
Antioxidants (Basel). 2021 Oct 30;10(11):. (PMID: 34829617)
BMC Cardiovasc Disord. 2023 Jan 10;23(1):11. (PMID: 36627571)
Oxid Med Cell Longev. 2020 Oct 7;2020:6801587. (PMID: 33101590)
Front Cardiovasc Med. 2022 Apr 13;9:845942. (PMID: 35498045)

Keywords: PKA; TRPV6; atherosclerosis; coronary artery disease; inflammatory response

0 (TRPV Cation Channels)
EC 2.7.11.11 (Cyclic AMP-Dependent Protein Kinases)
0 (TRPV6 protein, human)
0 (Uncoupling Protein 2)
0 (Calcium Channels)
0 (Inflammation Mediators)
0 (Cytokines)
0 (Lipoproteins, LDL)
0 (oxidized low density lipoprotein)

Date Created: 20250101 Date Completed: 20250101 Latest Revision: 20250104

20250114

PMC11524718

10.1155/2024/7053116

39742020